BEAM vs CRSP
BEAM: Beam Therapeutics is developing base editing medicines—a precision genetic cure approach—for serious inherited diseases like sickle cell disease and rare genetic disorders. CRSP: CRISPR Therapeutics develops gene-editing medicines using CRISPR/Cas9 technology, with the first approved CRISPR therapy (CASGEVY) for sickle cell disease and beta thalassemia, plus a pipeline of in vivo and cell therapy programs.
Side-by-side fundamentals
| Metric | BEAM | CRSP | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $26.64 | $47.24 | |
| Market cap as of 2026-07-23 | $2.7B | $4.6B | |
| PEG as of 2026-07-23 | n/a | -0.21 | |
| Net margin as of 2026-07-23 | -39.7% | -13856.5% | BEAM higher |
| Operating margin as of 2026-07-23 | -226.6% | -15754.2% | BEAM higher |
| ROE as of 2026-07-23 | -5.9% | -30.9% | BEAM higher |
| ROA as of 2026-07-23 | -4.6% | -24.5% | BEAM higher |
| Debt / equity as of 2026-07-23 | 0.09 | 0.32 | BEAM lower |
| Revenue growth (YoY) as of 2026-07-23 | +158.0% | -89.1% | BEAM higher |
| Revenue CAGR (3y) SEC XBRL | +31.9% | +43.1% | CRSP higher |
| Beta as of 2026-07-23 | 2.22 | 1.77 | |
| 1-year return as of 2026-07-22 close | +29.8% | -26.3% | BEAM higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.